Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib.
Betacoronavirus
/ immunology
COVID-19
Coronavirus Infections
/ diagnosis
Graft vs Host Disease
/ drug therapy
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Immunocompromised Host
Lymphoma, T-Cell
/ immunology
Male
Middle Aged
Nitriles
Pandemics
Pneumonia, Viral
/ diagnosis
Pyrazoles
/ therapeutic use
Pyrimidines
SARS-CoV-2
Severity of Illness Index
Transplantation, Homologous
/ adverse effects
Treatment Outcome
COVID-19 Drug Treatment
Allogeneic stem cell transplantation
COVID-19
Graft-versus-host disease
Immunocompromised
JAK inhibitor
Journal
Clinical lymphoma, myeloma & leukemia
ISSN: 2152-2669
Titre abrégé: Clin Lymphoma Myeloma Leuk
Pays: United States
ID NLM: 101525386
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
11
05
2020
revised:
16
06
2020
accepted:
22
06
2020
pubmed:
31
7
2020
medline:
18
11
2020
entrez:
31
7
2020
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has a high death rate in patients with comorbidities or in an immunocompromised state. We report a mild and attenuated SARS CoV-2 infection in a patient who is 17 months post stem cell transplantation and maintained on the JAK/STAT inhibitor ruxolitinib, a proposed novel therapy for SARS CoV-2 pneumonia.
Identifiants
pubmed: 32727701
pii: S2152-2650(20)30312-8
doi: 10.1016/j.clml.2020.06.014
pmc: PMC7316063
pii:
doi:
Substances chimiques
Nitriles
0
Pyrazoles
0
Pyrimidines
0
ruxolitinib
82S8X8XX8H
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
720-723Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
Copyright © 2020. Published by Elsevier Inc.
Références
Bone Marrow Transplant. 2018 Jul;53(7):826-831
pubmed: 29367708
Ann Hematol. 2018 May;97(5):913-914
pubmed: 29340760
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Growth Factors. 2012 Apr;30(2):88-106
pubmed: 22339650
Biol Blood Marrow Transplant. 2017 Jul;23(7):1122-1127
pubmed: 28344057
Radiol Cardiothorac Imaging. 2020 Mar 25;2(2):e200152
pubmed: 33778571
J Autoimmun. 2020 May;109:102442
pubmed: 32253068
Chin Med J (Engl). 2020 May 5;133(9):1015-1024
pubmed: 32004165
J Chin Med Assoc. 2020 Jun;83(6):534-536
pubmed: 32243270
IDrugs. 2010 Jun;13(6):394-403
pubmed: 20506062
Ecancermedicalscience. 2020 Mar 27;14:1022
pubmed: 32256705
Blood. 2014 Jun 12;123(24):3832-42
pubmed: 24711661
J Hematol Oncol. 2016 Aug 08;9(1):67
pubmed: 27502249
Inflamm Res. 2020 Jan;69(1):51-62
pubmed: 31654094
Blood. 2010 Apr 15;115(15):3109-17
pubmed: 20130243
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Invest Dermatol. 2011 Sep;131(9):1838-44
pubmed: 21677670
Nat Rev Microbiol. 2020 Mar;18(3):123
pubmed: 31988490
Clin Cancer Res. 2015 Aug 15;21(16):3740-9
pubmed: 25977345
J Transl Med. 2020 Apr 14;18(1):164
pubmed: 32290839
Mod Pathol. 2020 Jun;33(6):1007-1014
pubmed: 32291399
Clin Immunol. 2020 May;214:108393
pubmed: 32222466